{"disease":{"id":"cancer-therapy-related-cardiac-dysfunction","name":"cancer therapy related cardiac dysfunction"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07515859","title":"Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography","phase":"","overall_status":"COMPLETED","enrollment_count":31486,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06881940","title":"Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":284,"lead_sponsor_name":"Instituto Nacional de Cardiologia Ignacio Chavez","has_results":false},{"nct_id":"NCT05732051","title":"Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University Hospital, Akershus","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}